Remove 2026 Remove Biopharma Remove Prescription
article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts

Clarivate

Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. To learn more about how Clarivate helps biopharma innovators navigate a fast-changing market access environment, please visit us our website.

article thumbnail

Beyond transparent pricing: decoding the strategies of major PBMs

Clarivate

Express Scripts ClearNetwork (effective from early 2024) Cost-plus pricing model; includes ESI’s 65,000-plus site retail pharmacy network; prescription pricing is based on the lowest of three benchmarks: NADAC, WAC or PAC; Pharmacies receive a flat dispensing fee plus up to 15% markup.

Retail 59
article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices.

FDA 52
article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

RxPass offers more than 50 select prescriptions at no additional cost for $5 per month. In classic Amazon style, its pharmacy offers two-day shipping on prescriptions by mail, with same-day delivery available in seven markets, with plans to add a dozen more cities by year end. Source: News reports and company releases.

Retail 52
article thumbnail

CMS enters drug price negotiation arena in sea change for industry

Clarivate

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.